Smith & Nephew (SNN) Competitors

Smith & Nephew (NYSE:SNN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability.

Does the media favor SNN or ZBH?

In the previous week, Zimmer Biomet had 6 more articles in the media than Smith & Nephew. MarketBeat recorded 12 mentions for Zimmer Biomet and 6 mentions for Smith & Nephew. Zimmer Biomet's average media sentiment score of 0.89 beat Smith & Nephew's score of 0.40 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SNN or ZBH a better dividend stock?

Smith & Nephew pays an annual dividend of $0.55 per share and has a dividend yield of 2.2%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.9%. Smith & Nephew pays out 27.9% of its earnings in the form of a dividend. Zimmer Biomet pays out 18.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Do analysts prefer SNN or ZBH?

Zimmer Biomet has a consensus price target of $123.22, suggesting a potential upside of 12.05%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Smith & Nephew.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zimmer Biomet	2 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.20

Is SNN or ZBH more profitable?

Zimmer Biomet has a net margin of 14.27% compared to Smith & Nephew's net margin of 0.00%. Zimmer Biomet's return on equity of 12.95% beat Smith & Nephew's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew	N/A	N/A	N/A
Zimmer Biomet	14.27%	12.95%	7.55%

Does the MarketBeat Community prefer SNN or ZBH?

Zimmer Biomet received 451 more outperform votes than Smith & Nephew when rated by MarketBeat users. Likewise, 67.24% of users gave Zimmer Biomet an outperform vote while only 54.43% of users gave Smith & Nephew an outperform vote.

Company	Underperform	Outperform
Smith & Nephew	Outperform Votes 448 54.43%	Underperform Votes 375 45.57%
Zimmer Biomet	Outperform Votes 899 67.24%	Underperform Votes 438 32.76%

Do insiders and institutionals have more ownership in SNN or ZBH?

25.6% of Smith & Nephew shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more risk & volatility, SNN or ZBH?

Smith & Nephew has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Which has better earnings and valuation, SNN or ZBH?

Zimmer Biomet has higher revenue and earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew	$5.55B	1.94	$263M	$1.97	12.49
Zimmer Biomet	$7.39B	2.96	$1.02B	$5.26	20.91

Summary

Zimmer Biomet beats Smith & Nephew on 17 of the 20 factors compared between the two stocks.